Mobile Commerce Platform Fintiv Partners with Geoswift to Enable Cross-border Digital Remittance in Asia
2.2.2023 23:16:00 EET | Business Wire | Press release
Fintiv, a leading mobile commerce platform that brings together payments, loyalty programs, and mobile marketing in one place, has partnered with Geoswift, a payment technology company with significant expertise in Asian cross-border payments, to enable digital remittance payments into Asia through Fintiv’s versatile mobile wallets.
The partnership will provide Fintiv’s customers the unique capability of making person-to-person or business-to-business payments into China, India, and many other Asian countries, directly from wallet accounts. With Geoswift’s superior geographical reach through its “GeoRemit” product line, Fintiv’s payment platform can now connect to an extensive number of domestic banks or mobile wallets in Asian countries and territories. For example, payments can be delivered instantly to either the UnionPay debit/credit cards or Alipay wallets of beneficiaries in China.
“We are proud to announce a partnership with Geoswift as part of our global digital currency network, and very excited to expand our reach into China and Hong Kong. Supporting Geoswift’s platform with Fintiv technology while enabling our clients to make payments and remittances in Yuan and Hong Kong Dollars is strategically beneficial”, said David Hanna, Chairman of Fintiv.
“Geoswift and Fintiv share an unwavering commitment to make the world a more mobile and connected place. This collaboration will give customers an exceptional digital payment experience with great convenience and efficiency, to connect with families, friends, or business partners overseas,” said Raymond Qu, founder and CEO of Geoswift.
About Fintiv
Fintiv is a global leader in mobile payments and digital banking, having deployed over 75 ecosystems in more than 35 countries, for clients serving more than 1.5 billion consumers. Fintiv is also a pioneer in mobile technology, having deployed the first mobile wallet in the USA in the early 2000s, resulting in explosive growth achieving Unicorn status by 2015. During the same period the company built one of the most significant and relevant patent portfolios globally, and is now managing over 150 patents. Fintiv operates several subsidiaries providing digital payments, commerce, and banking services.
About Geoswift
Geoswift is an innovative, globalized payment technology company, with a distinct niche in Asian cross-border payments. Since its inception in 2010, the name Geoswift has been synonymous with frictionless cross-border fund flows throughout the world. Geoswift is a leading authorized payment service provider in the US, UK and China, offering global acquiring and issuing capabilities for key financial institutions. Widely recognized for its proprietary technologies, extensive knowledge of global and local regulatory requirements, strong banking networks, and global operations, Geoswift provides a customized one-stop cross-border payment solution to businesses of any size. In addition, Geoswift runs several currency exchange stores throughout China. Headquartered in Vancouver, Geoswift has regional offices in Beijing, Hong Kong, Shanghai, San Francisco, London, Singapore and Shenzhen – offering payment solutions to clients globally.
For more information, visit Geoswift.com or Fintivtech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201006142/en/
Contact information
Geoswift:
Annie Lin
Email: annie.lin@geoswift.com
Phone: +1 604 638 8182
Fintiv:
Mike Love
Email: Mike.love@fintiv.global
Phone: +1 512 964 5789
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom